Loading…
The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges
Khan, Shahzadgai, Albayaty, Muna, Bush, James, Cheriyan, Joseph, Cromie, Anthea, Koch, Annelize, Hammond, Michael, Mair, Stuart, Lorch, Ulrike, Stringer, Steffan, Taubel, Jorg, Hardman, Timothy C.
Published in Frontiers in pharmacology (19.11.2020)
Published in Frontiers in pharmacology (19.11.2020)
Get full text
Journal Article
Loading…
Loading…
Loading…
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease: First small molecule allosteric binder discovered with Gain’s computational drug discovery platform enters clinical development
Published in NASDAQ OMX's News Release Distribution Channel
(04.10.2023)
Get full text
Newsletter
Loading…
Loading…
Loading…
Federal Grant: DoD Amyotrophic Lateral Sclerosis, Clinical Development Award
Published in US Fed News Service, Including US State News
(20.02.2021)
Get full text
Newsletter
Loading…
Role of pharmacogenetic studies in early clinical development: Phase I studies with lapatinib
Zaks, T. Z., Akkari, A., Briley, L., Mosteler, M., Stead, A. G., Koch, K. M., Sampson, C., Ehm, M., Harris, E., Roses, A.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article
Loading…
Loading…
Clinical development and evolution in plaque removal performance of a battery powered toothbrush
Claydon, N., Moran, J., Newcombe, R. G., Smith, S. R., Addy, M.
Published in Journal of clinical periodontology (01.10.2004)
Published in Journal of clinical periodontology (01.10.2004)
Get full text
Journal Article
Loading…
Gannex Announces Positive Topline Results from the U.S. Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRβ Agonist ASC41: Drug-Drug interactions of ASC41/ASC41-A with strong CYP3A4 inhibitor or inducer were low, showing competitiveness to other THRβ agonists in the late stage clinical development
Published in PR Newswire Asia
(07.09.2021)
Get full text
Newsletter